A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
116actual
Sites
1
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-13 | actual | When the study began enrolling |
| Primary completion | 2025-11-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-10 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Chronic Kidney Disease
Interventions
- Drug: NNC0705-0001
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPART A: Number of treatment emergent adverse events (TEAE)
measured From time of dosing (day 1) to end of study (day 7)
PART B: Number of TEAEs
measured From time of dosing (day 1) to end of study (day 13)
AUC, SD; the area under the NNC0705-0001 plasma concentration-time curve after a single dose
measured From pre-dose (day 1 or day 8) to day 2 or day 9
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed